These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 17226739)

  • 21. Alzheimer's disease.
    Honig LS; Chin SS
    Sci Aging Knowledge Environ; 2001 Oct; 2001(1):dn2. PubMed ID: 14602942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Morphological substrates of cognitive decline in nonagenarians and centenarians: a new paradigm?
    Imhof A; Kövari E; von Gunten A; Gold G; Rivara CB; Herrmann FR; Hof PR; Bouras C; Giannakopoulos P
    J Neurol Sci; 2007 Jun; 257(1-2):72-9. PubMed ID: 17303173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biomarkers for Alzheimer's disease.
    Ward M
    Expert Rev Mol Diagn; 2007 Sep; 7(5):635-46. PubMed ID: 17892369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early-onset Alzheimer's disease is associated with greater pathologic burden.
    Marshall GA; Fairbanks LA; Tekin S; Vinters HV; Cummings JL
    J Geriatr Psychiatry Neurol; 2007 Mar; 20(1):29-33. PubMed ID: 17341768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
    Cacabelos R
    Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A permanent pure amnestic syndrome of insidious onset related to Alzheimer's disease.
    Didic M; Ali Chérif A; Gambarelli D; Poncet M; Boudouresques J
    Ann Neurol; 1998 Apr; 43(4):526-30. PubMed ID: 9546336
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).
    Koopman K; Le Bastard N; Martin JJ; Nagels G; De Deyn PP; Engelborghs S
    Neurochem Int; 2009 Sep; 55(4):214-8. PubMed ID: 19524111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential neuropsychological patterns of frontal variant frontotemporal dementia and Alzheimer's disease in a study of diagnostic concordance.
    Giovagnoli AR; Erbetta A; Reati F; Bugiani O
    Neuropsychologia; 2008 Apr; 46(5):1495-504. PubMed ID: 18262206
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 2008 Alzheimer's disease facts and figures.
    Alzheimer's Association
    Alzheimers Dement; 2008 Mar; 4(2):110-33. PubMed ID: 18631956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple sclerosis and Alzheimer's disease.
    Dal Bianco A; Bradl M; Frischer J; Kutzelnigg A; Jellinger K; Lassmann H
    Ann Neurol; 2008 Feb; 63(2):174-83. PubMed ID: 17924575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuropathology of Alzheimer's disease.
    Mott RT; Hulette CM
    Neuroimaging Clin N Am; 2005 Nov; 15(4):755-65, ix. PubMed ID: 16443488
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathological correlates of cognitive decline in Alzheimer's disease.
    Thind K; Sabbagh MN
    Panminerva Med; 2007 Dec; 49(4):191-5. PubMed ID: 18091671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Homozygosity for the K variant of BCHE gene increases the risk for development of neurofibrillary pathology but not amyloid deposits at young ages.
    Ghebremedhin E; Thal DR; Schultz C; Braak H; Deller T
    Acta Neuropathol; 2007 Oct; 114(4):359-63. PubMed ID: 17701416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alzheimer disease and its management: a review.
    Samanta MK; Wilson B; Santhi K; Kumar KP; Suresh B
    Am J Ther; 2006; 13(6):516-26. PubMed ID: 17122533
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effective recognition and diagnosis of dementia.
    Geldmacher DS
    Semin Neurol; 2002 Mar; 22(1):63-70. PubMed ID: 12170394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Alzheimer's disease].
    Tanii H; Takeda M
    Ryoikibetsu Shokogun Shirizu; 2003; (40):243-7. PubMed ID: 14626111
    [No Abstract]   [Full Text] [Related]  

  • 39. Thiazin red as a neuropathological tool for the rapid diagnosis of Alzheimer's disease in tissue imprints.
    Luna-Muñoz J; Peralta-Ramirez J; Chávez-Macías L; Harrington CR; Wischik CM; Mena R
    Acta Neuropathol; 2008 Nov; 116(5):507-15. PubMed ID: 18810470
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-products (TAGE) in early detection of Alzheimer's disease.
    Takeuchi M; Sato T; Takino J; Kobayashi Y; Furuno S; Kikuchi S; Yamagishi S
    Med Hypotheses; 2007; 69(6):1358-66. PubMed ID: 17888585
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.